Respuesta a la réplica de Van den Reek et al. a: El análisis de supervivencia no es un buen método para evaluar la seguridad o la efectividad de los tratamientos sistémicos en psoriasis
Authors:
- 1 September 2017
- journal article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (7) , 697-698
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysisJournal of the European Academy of Dermatology and Venereology, 2016
- Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Journal of the European Academy of Dermatology and Venereology, 2016
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Journal of Investigative Dermatology, 2015
- Drug Survival Studies in Dermatology:Principles, Purposes, and PitfallsJournal of Investigative Dermatology, 2015
- Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgarisBritish Journal of Dermatology, 2014
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTUREnetworkBritish Journal of Dermatology, 2014